Patents by Inventor Keld Dano
Keld Dano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080171691Abstract: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.Type: ApplicationFiled: January 24, 2008Publication date: July 17, 2008Inventors: Leif Roge Lund, Keld Dano, Ross Stephens, Nils Brunner, Helene Solberg, Claus Holst-Hansen, John Romer Nielsen
-
Publication number: 20080166354Abstract: The present invention relates to methods for inhibiting malignant tumour growth, invasion and/or metastasis in a patient, the method comprising suppressing the inhibitory activity of an inhibitor of a protease or of a non-proteolytic matrix-degrading enzyme (IPNME) in malignant tumour tissue or potential malignant tumour tissue. The suppression may be brought about by administering compounds interacting with the IPNME, but also administration of compounds interacting with transcription of genes encoding the IPNME is a possibility. The invention also relates to methods of selecting and identifying compounds in the therapeutical methods, as well of the use of such compounds in the treatment of malignancies.Type: ApplicationFiled: December 26, 2007Publication date: July 10, 2008Inventors: Niels Brunner, John Romer, Vincent Ellis, Charles Pyke, Jan Grondahl-Hansen, Helle Pedersen Pappot, Heine Hoi Hansen, Keld Dano
-
Patent number: 7026282Abstract: A novel set of inhibitors of the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR) has been developed. The inhibitors comprise of peptide fragments, monomeric or in multiple copies attached to a common scaffold, in which the amino acid sequence may include uncommon substituted amino acids to partially comprise of peptoid sequences. The present invention also relates to the use of such peptides in therapy, in particular for the treatment of cancer, having developed a modified non-human mammalian receptor to which the novel inhibitors are antagonistic.Type: GrantFiled: July 1, 1999Date of Patent: April 11, 2006Assignee: Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning)Inventors: Michael Ploug, Søren Østergaard, Claus Holst-Hansen, Ross Stephens, Keld Danø, Arne Holm
-
Publication number: 20050137121Abstract: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.Type: ApplicationFiled: September 29, 2004Publication date: June 23, 2005Inventors: Leif Lund, Keld Dano, Ross Stephens, Nils Brunner, Helene Solberg, Claus Holst-Hansen, John Nielsen
-
Publication number: 20030096755Abstract: The present invention relates to methods for inhibiting malignant tumour growth, invasion and/or metastasis in a patient, the method comprising suppressing the inhibitory activity of an inhibitor of a protease or of a non-proteolytic matrix-degrading enzyme (IPNME) in malignant tumour tissue or potential malignant tumour tissue. The suppression may be brought about by administering compounds interacting with the IPNME, but also administration of compounds interacting with transcription of genes encoding the IPNME is a possibility. The invention also relates to methods of selecting and identifying compounds in the therapeutical methods, as well of the use of such compounds in the treatment of malignancies.Type: ApplicationFiled: January 2, 2003Publication date: May 22, 2003Inventors: Niels Brunner, John Romer, Vincent Ellis, Charles Pyke, Jan Grondahl-Hansen, Helle Pedersen Pappot, Heine Hoi Hansen, Keld Dano
-
Publication number: 20030027981Abstract: A polypeptide presenting an epitope cross-reactive with an epitope of urokinase-type plasminogen activator receptor, and/or having uPA binding activity, is described.Type: ApplicationFiled: January 8, 2001Publication date: February 6, 2003Inventors: Keld Dano, Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, Wolf-Dieter Schleuning, Niels Behrendt, Ebbe Ronne, Peter Kristensen, Jari Pollanen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk Moller, Vincent Ellis, Leif Roge Lund, Michael Ploug, Charles Pyke, Laszlo Patthy
-
Publication number: 20020099004Abstract: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.Type: ApplicationFiled: November 29, 2001Publication date: July 25, 2002Inventors: Leif Roge Lund, Keld Dano, Ross Stephens, Nils Brunner, Helene Solberg, Claus Holst-Hansen, John Romer Nielsen
-
Publication number: 20020012950Abstract: A monoclonal antibody which binds a human endothelial type plasminogen activator inhibitor (PAI-1) produced by dexamethasone-treated human HT-1080 fibrosarcoma cells may be used, inter alia, for determining PAI-1 protein abundance in tumor tissue or a sample of a body fluid. Measurements of this parameter may be useful in predicting the presence or metastasis of a tumor, or of predicting the progression of a known malignant tumor.Type: ApplicationFiled: August 7, 2001Publication date: January 31, 2002Inventors: Lars S. Nielsen, Peter Andreasen, Keld Dano, Nils Brunner
-
Publication number: 20010034327Abstract: The present invention relates to methods for inhibiting malignant tumour growth, invasion and/or metastasis in a patient, the method comprising suppressing the inhibitory activity of an inhibitor of a protease or of a non-proteolytic matrix-degrading enzyme (IPNME) in malignant tumour tissue or potential malignant tumour tissue. The suppression may be brought about by administering compounds interacting with the IPNME, but also administration of compounds interacting with transcription of genes encoding the IPNME is a possibility. The invention also relates to methods of selecting and identifying compounds in the therapeutical methods, as well of the use of such compounds in the treatment of malignancies.Type: ApplicationFiled: April 18, 2001Publication date: October 25, 2001Inventors: Niels Brunner, John Romer, Vincent Ellis, Charles Pyke, Jan Grondahl-Hansen, Helle Pedersen Pappot, Heine Hoi Hansen, Keld Dano
-
Patent number: 6271352Abstract: a monoclonal antibody which binds a human endothelial type plasminogen activator inhibitor (PAI-1) produced by dexamethasone-treated human HT-1080 fibrosarcoma cells may be used, inter alia, for determining PAI-1 protein abundance in tumor tissue or a sample of a body fluid. Measurements of this parameter may be useful in predicting the presence or metastasis of a tumor, or of predicting the progression of a known malignant tumor.Type: GrantFiled: June 6, 1995Date of Patent: August 7, 2001Assignee: Fonden til Fremme af Eksperimentel CancerforskningInventors: Lars S. Nielsen, Peter Andreasen, Keld Dano, Nils Brunner
-
Patent number: 6248712Abstract: Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.Type: GrantFiled: May 16, 1995Date of Patent: June 19, 2001Assignee: Cancerforskningsfondet af 1989Inventors: Keld Danø, Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, W.D. Schleuning, Niels Behrendt, Ebbe Rønne, Peter Kristensen, Jari Pöllänen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk Møller, Vincent Ellis, Leif Røge Lund, Michael Ploug, Charles Pyke, Lászl{acute over (o )} Patthy
-
Patent number: 6224865Abstract: The present invention relates to methods for inhibiting malignant tumour growth, invasion and/or metastasis in a patient, the method comprising suppressing the inhibitory activity of an inhibitor of a protease or of a non-proteolytic matrix-degrading enzyme (IPNME) in malignant tumour tissue or potential malignant tumour tissue. The suppression may be brought about by administering compounds interacting with the IPNME, but also administration of compounds interacting with transcription of genes encoding the IPNME is a possibility. The invention also relates to methods of selecting and identifying compounds in the therapeutical methods, as well of the use of such compounds in the treatment of malignancies.Type: GrantFiled: May 15, 1996Date of Patent: May 1, 2001Assignee: Cancerforskningsfonden AF 1989Inventors: Nils Brünner, John Rømer, Vincent Ellis, Charles Pyke, Jan Grøndahl-Hansen, Helle Pedersen, Heine Høi Hansen, Keld Danø
-
Patent number: 5519120Abstract: A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal.Type: GrantFiled: June 17, 1993Date of Patent: May 21, 1996Assignee: Cancerforskningsfondet af 1989Inventors: Keld Dano, Ebbe Ronne, Niels Behrendt, Vincent Ellis, Gunilla Hoyer-Hansen, Charles Pyke, Nils Bruenner
-
Patent number: 5422245Abstract: In a method of producing monoclonal antibodies against endothelial type plasminogen activator inhibitor and immunologically similar inhibitors myeloma cells are fused with antibody-producing cells obtained from mammals which have been immunized with said plasminogen activator inhibitor or with antibody-producing cells, which in vitro have been immunized with said plasminogen activator inhibitor and the hybridomas producing antibodies against the above mentioned inhibitor are selected. The antibody-producing cells are preferably spleen cells or lymph node cells, most preferably spleen cells, obtained from mice immunized with the above mentioned inhibitor.Type: GrantFiled: June 18, 1992Date of Patent: June 6, 1995Assignee: Fonden Til Fremme AF Eksperimental CancerforskningInventors: Lars S. Nielsen, Peter A. Andreasen, Keld Dano